NCT06050798

Brief Summary

The study aim will be to assess the association between GIT angiodysplasia with any hematological disorders such as any specific coagulation disorders or anemia.

Trial Health

65
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
55

participants targeted

Target at P25-P50 for all trials

Timeline
4mo left

Started Jun 2024

Typical duration for all trials

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress83%
Jun 2024Oct 2026

First Submitted

Initial submission to the registry

September 16, 2023

Completed
6 days until next milestone

First Posted

Study publicly available on registry

September 22, 2023

Completed
8 months until next milestone

Study Start

First participant enrolled

June 1, 2024

Completed
2.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2026

Expected
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

October 1, 2026

Last Updated

May 2, 2024

Status Verified

April 1, 2024

Enrollment Period

2.3 years

First QC Date

September 16, 2023

Last Update Submit

April 30, 2024

Conditions

AngiodysplasiaHematological Disease

Outcome Measures

Primary Outcomes (1)

  • Hematological disorder in patients with angiodysplasia

    Von willebrand antigen change and anemia and impaired coagulation profile in angiodysplasia

    Baseline

Interventions

Von willebrand antigenDIAGNOSTIC_TEST

Von willebrand antigen change and hematological disorder in patients with angiodysplasia

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients with angiodysplasia

You may qualify if:

  • Adults (above 18 years) and elderly
  • Both genders
  • Admitted to GIT Unit with manifestations of GIT angiodysplasia diagnosed by upper endoscopy and Colonoscopy.
  • bleeding git symptoms

You may not qualify if:

  • other causes ofGIT bleeding
  • bleeding git ulcers
  • hematological disorder causing bleeding tendency ex hemophilia

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (1)

  • Selvam S, James P. Angiodysplasia in von Willebrand Disease: Understanding the Clinical and Basic Science. Semin Thromb Hemost. 2017 Sep;43(6):572-580. doi: 10.1055/s-0037-1599145. Epub 2017 May 5.

    PMID: 28476066BACKGROUND

MeSH Terms

Conditions

AngiodysplasiaHematologic Diseases

Condition Hierarchy (Ancestors)

Vascular DiseasesCardiovascular DiseasesHemic and Lymphatic Diseases

Study Officials

  • AbdelHamid Mohamed AbdelHamid Aly

    Assiut University

    STUDY CHAIR

  • Nabeela Faiek Amin Mousa

    Assiut University

    STUDY CHAIR

Central Study Contacts

Lydia Mamdouh Sadek

CONTACT

01098293921lydia.mamdouh97@gmail.com

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assistant lecturer

Study Record Dates

First Submitted

September 16, 2023

First Posted

September 22, 2023

Study Start

June 1, 2024

Primary Completion (Estimated)

September 1, 2026

Study Completion (Estimated)

October 1, 2026

Last Updated

May 2, 2024

Record last verified: 2024-04